Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in High-Burden Prurigo Nodularis
NCT07620561Phase 2Not yet recruiting
- Sponsor
- University of Maryland, Baltimore
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of lebrikizumab in prurigo nodularis (PN), sponsored by University of Maryland, Baltimore. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
lebrikizumab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT07620561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07620561.